Siemens Healthcare Diagnostics AND B-R-A-H-M-S AKTIENGESELLSCHAFT AGREE TO DEVELOP PROCALCITONIN (PCT) ASSAY ON SIEMENS IMMUNOASSAY PLATFORMS

New Assay Targeted for Siemens ADVIA Centaur and Immulite Family of Immunoassay Analyzers

Tarrytown, NY, November 5, 2007 – Siemens Healthcare Diagnostics, a leader in the in vitro diagnostic industry, announced that they have signed an agreement with B-R-A-H-M-S Aktiengesellschaft for the rights to develop, produce and distribute a Procalcitonin assay used to assist with the early diagnosis of patients at risk for progression to severe sepsis.

"Early diagnosis and appropriate therapy of sepsis is a daily challenge in intensive care units," said Joe Bernardo, senior vice president, Central Lab Testing, Siemens Healthcare Diagnostics. "This agreement highlights the enormous potential to help attending physicians recognize clinically relevant bacterial infections and estimate the risk of a septic complication, which can often have fatal consequences. Our goal is to focus on new opportunities to provide the diagnostic tools necessary to diagnose and treat millions of patients. This collaboration demonstrates our commitment to that goal."

Severe sepsis (sepsis with acute organ dysfunction) is the number one cause of death in the non-coronary intensive care unit. Today, more than 750,000 Americans develop severe sepsis each year equaling to more than 2,000 new cases per day in the U.S. Cases of severe sepsis are expected to rise partly due to the widespread use of antibiotics which encourages the growth of drug resistant microorganisms . Despite the enormous investment in critical care resources, severe sepsis mortality ranges from 28 percent to 50 percent or greater.

"The co-operation with Siemens Healthcare Diagnostics for now completes our strategic alliances on Procalcitonin aimed to allow diagnostic laboratories all over the world the access to one of the clinically most relevant biomarkers," stated Herbert Sucka, chief marketing officer of B-R-A-H-M-S. "It is part of our business model to gain global market coverage with our patented novel markers under the B-R-A-H-M-S trademark jointly with globally operating strategic collaborators. This also applies to our next generation of cardiac and infection markers which is currently evaluated in international multi-centric trials."

B-R-A-H-M-S Aktiengesellschaft will have the exclusive distribution rights in relevant European markets for the PCT test manufactured by Siemens Healthcare Diagnostics under B-R-A-H-M-S'  license. Siemens will distribute the test to markets outside Europe. The PCT test has already received regulatory approvals in Japan and the USA. Outside of Europe, the licensed PCT test will be available on both the ADVIA® Centaur® and IMMULITE® platforms from Siemens, whereas in Europe the licensed PCT test will only be available on the ADVIA® Centaur® platform.

About B-R-A-H-M-S Aktiengesellschaft 
Under the B-R-A-H-M-S Trademark innovative biomarker tests for the diagnosis of medically and economically relevant diseases are distributed worldwide through the company's own organisations, distributors and licensees. Based on its extensive proteomic research program B-R-A-H-M-S with its more than 300 employees continuously identifies innovative biomarkers to the benefit of severely ill patients which extend the large patent portfolio of the company. A brand new panel of patented novel biomarkers to further improve diagnosis and therapy monitoring of patients with cardiac and infectious diseases are currently evaluated in extended international multicentric clinical trial projects. The B-R-A-H-M-S Aktiengesellschaft has its headquarters in Hennigsdorf near Berlin, Germany and can be found at
www.brahms.de
www.procalcitonin.com

About Siemens Healthcare Diagnostics 
Siemens Healthcare Diagnostics offers a broad portfolio of performance-driven diagnostic solutions that assist in the diagnosis, monitoring and management of disease. Products and services bring together the right balance of science, technology, and practicality across the healthcare continuum to empower medical professionals with the vital information they need to deliver better, more personalized healthcare to patients around the globe. Visit us at:
www.siemens.com/diagnostics

About Siemens Medical Solutions 
Siemens Medical Solutions of Siemens AG (NYSE: SI) is one of the world's largest suppliers to the healthcare industry. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Recent acquisitions in the area of in-vitro diagnostics – such as Diagnostic Products Corporation and Bayer Diagnostics – mark a significant milestone for Siemens as it becomes the first full service diagnostics company. Employing more than 41,000 people worldwide and operating in over 130 countries, Siemens Medical Solutions reported sales of 8.23 billion EUR, orders of 9.33 billion EUR and group profit of 1.06 billion EUR for fiscal 2006 (Sept. 30). Further information can be found by visiting
www.usa.siemens.com/medical-pressroom